Published on 21/12/2025
Leveraging WHO ICTRP and International Registries for Global Trial Transparency
Introduction: Why Global Registration Matters
While national regulations like FDAAA or EU CTR mandate trial registration and result posting, clinical research increasingly spans multiple countries. Ensuring visibility across jurisdictions requires using globally recognized platforms such as the World Health Organization’s International Clinical Trials Registry Platform (ICTRP) and its partner registries.
The ICTRP acts as a unifying hub for clinical trial information, ensuring that trials conducted anywhere in the world—especially in low- and middle-income countries—are not lost in isolated or non-compliant databases. It supports the principles of ethical conduct, participant protection, and public trust in clinical research by making information freely accessible regardless of geography or outcome.
What Is the WHO ICTRP?
Launched in 2006, the WHO ICTRP is a global initiative designed to ensure that clinical trials are registered and publicly accessible through a single search portal. It doesn’t host original trial records but aggregates data from over 20 approved primary and partner registries that meet WHO standards.
To qualify for inclusion, a registry must provide open access, require prospective registration, follow standard technical and governance protocols, and capture the WHO’s 20-item Trial Registration
Key Partner Registries in the ICTRP Network
ICTRP consolidates trial records from approved national and regional registries, including:
- CTRI (India)
- ANZCTR (Australia/New Zealand)
- ISRCTN (UK)
- JPRN (Japan)
- ReBEC (Brazil), ChiCTR (China), PACTR (Africa), among others
Each registry retains control of its own data submission and update mechanisms. However, they synchronize regularly with ICTRP to ensure visibility and aggregation into the global search interface, trialsearch.who.int.
WHO’s 20-Item Minimum Dataset (TRDS)
All registries in the ICTRP network must collect the WHO’s minimum dataset, including:
- Trial identification number
- Scientific and public titles
- Interventions and comparators
- Primary and secondary outcomes
- Recruitment countries and target size
- Sponsor and funding sources
- Ethics approval status
- Study phase and design
This harmonization ensures that researchers, clinicians, regulators, and the public can compare trials across countries and avoid duplicative or conflicting information.
Benefits of Registering in WHO-Linked Registries
Registering a trial in a recognized ICTRP partner registry offers several advantages:
- Global Visibility: Enables international searchability and collaboration
- Compliance with ICMJE: Satisfies requirements for manuscript publication in leading journals
- Research Integrity: Reduces publication bias and selective reporting
- Trial Tracking: Allows patients and advocates to follow ongoing research
- Funding Eligibility: Meets disclosure criteria of NIH, Wellcome Trust, and others
For multicountry trials, listing in an ICTRP-linked registry ensures synchronized data visibility without requiring registration in every individual country.
Example: Using CTRI for Indian Trials
The Clinical Trials Registry of India (CTRI) is mandatory for all trials conducted in India. It requires prospective registration before enrollment and collects the full WHO dataset.
Once published, CTRI entries are automatically indexed in the WHO ICTRP database. Indian researchers or global sponsors can thereby meet local and global disclosure expectations through a single registration action.
Multilingual Access and Low-Income Country Inclusion
One unique aspect of ICTRP is its emphasis on inclusivity. Registries are encouraged to offer multilingual access, simplified public summaries, and compatibility with low-bandwidth environments.
For example, PACTR (Pan-African Clinical Trials Registry) and ReBEC (Brazil) focus on enhancing trial visibility in regions historically underrepresented in global research databases. This helps balance equity and scientific representation.
How to Search and Navigate the ICTRP
Researchers, journalists, and patients can search trialsearch.who.int using parameters like study title, disease, country, registry ID, or sponsor. Results display matched records from all partner registries, ensuring that even trials registered in developing countries are visible alongside those in high-income nations.
Example query: Searching “Type 1 Diabetes India” retrieves CTRI trials along with ISRCTN- or JPRN-indexed global studies, enabling easy cross-referencing of intervention strategies and recruitment trends.
Challenges in Registry Harmonization
Despite its benefits, ICTRP faces challenges:
- Data Quality Inconsistencies: Variability in how registries populate mandatory fields
- Update Lag: Time delays in syncing registry updates with ICTRP
- Limited Layperson Accessibility: Many registries use technical language without patient-friendly summaries
- No Centralized Results Posting: Unlike ClinicalTrials.gov, ICTRP does not accept results submissions—it depends on source registries
Efforts are ongoing to standardize formats, improve data completeness, and enhance multilingual support.
Best Practices for Sponsors Using Global Registries
Sponsors planning international trials should adopt a disclosure strategy that includes:
- Selecting a WHO-compliant registry relevant to the trial location
- Registering all trials prospectively—even those in early phases
- Using a disclosure calendar to track registry update deadlines
- Harmonizing information across registries to avoid contradictions
- Ensuring the Trial Registration Number (TRN) is included in publications
Where possible, sponsors should also register early-phase and observational studies to foster public goodwill and signal transparency commitment.
Conclusion: ICTRP as a Global Pillar of Trial Transparency
The WHO ICTRP and its network of partner registries form the backbone of global clinical trial transparency. By providing free, aggregated access to trial information from around the world, it levels the playing field for research equity, public trust, and scientific progress.
Sponsors, investigators, and regulators must treat global registry participation not as an administrative obligation, but as a fundamental element of ethical, responsible research. In a world of interconnected science, global visibility is a prerequisite for global credibility.